📢 Announcing The Mark Foundation 2026 Emerging Leader Award winners! 📢

We are committing $3.75 million to 5 visionary early-career scientists poised to lead the next generation of oncology breakthroughs. We can't wait to see their impact!
themarkfoundation.org/2026/01/2026...

Effective targeting of PDGFRA-altered high-grade glioma with avapritinib PDGFRA is commonly altered in pediatric HGG. Mayr et al. report that the PDGFRA/KIT inhibitor avapritinib demonstrates on-target activity, brain penetrance, and survival benefit in pre-clinical H3K27M...

Thrilled to share our work with Mariella Filbin, Johannes Gojo and Carl Koschmann, now published in @cp-cancercell.bsky.social We present a translational approach identifying the PDGFRA inhibitor avapritinib as a novel targeted treatment for pHGG with PDGFRA alterations www.cell.com/cancer-cell/...

Safeguarding the future of biomedical science in the United States NIH’s abrupt decision to cap indirect cost reimbursement at 15% threatens the critical infrastructure supporting groundbreaking biomedical research in the United States. This policy jeopardizes America’s global leadership in science and medicine. Urgent…

Now online! Safeguarding the future of biomedical science in the United States

Mapping the developmental trajectory of human astrocytes reveals divergence in glioblastoma Nature Cell Biology - Sojka et al. analyse the transcriptomic and epigenomic landscape of human astrocyte maturation and identify an epigenetically regulated intermediate state associated with...

First 🦋 post! Very excited to share our lab's latest work exploring the shared and divergent aspects of human astrocyte development and glioblastoma. This effort spans many fields from developmental #glial biology to #stem cells and #tumor biology. rdcu.be/d5ADz A 🧵

Would love to be added as well. Thank you!